nach oben

Digestive Diseases and Sciences

Erschienen in:

06.01.2024 | Original Article

Obesity Is Associated with Altered Rectal Sensitivity in Chronic Constipation

verfasst von: Nayna A. Lodhia, Brent Hiramoto, Laura Horton, Alison H. Goldin, Christopher C. Thompson, Walter W. Chan

Erschienen in: Digestive Diseases and Sciences | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Defecation dysfunction may contribute to chronic constipation (CC), but the impact of obesity on anorectal physiology in CC remains unclear. We aimed to evaluate the relationship between obesity and anorectal function on physiologic testing in patients presenting with CC.

Methods

This was a retrospective cohort study of consecutive adults who underwent high resolution anorectal manometry (HRAM) at a tertiary center for CC. Patient demographics, clinical history, surgical/obstetric history, medications, and HRAM results were reviewed. Patients were classified into obese (BMI > 30 kg/m²) vs non-obese (BMI < 30 kg/m²) groups at the time of HRAM. Fisher-exact/student t-test for univariate analyses and general linear regression for multivariable analysis were performed.

Results

383 adults (mean 50.3 years; 85.8% female) with CC were included. On HRAM, patients with obesity had lower anal sphincter resting tone (37.3 vs 48.5 mmHg, p = 0.005) and maximum squeeze pressure (104.8 mmHg vs 120.0 mmHg, p = 0.043). No significant differences in dyssynergia (61% vs 53%, p = 0.294) and failed balloon expulsion (18% vs 25%, p = 0.381) were found between obese and non-obese groups. On balloon distention testing, the maximum tolerated (163.5 vs 147.6 mL, p = 0.042) and urge sensation (113.9 vs 103.7 mL, p = 0.048) volumes were significantly increased among patients with obesity. After adjusting for potential confounders, obesity remained independently associated with increased maximum tolerated volume (β-coefficient 13.7, p = 0.049).

Conclusion

Obesity was independently associated with altered rectal sensitivity among patients with CC. Altered rectal sensation may play an important role in CC among patients with obesity. Anorectal physiology testing should be considered to understand the pathophysiology and guide management.

Stewart WF, Liberman JN, Sandler RS et al. Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features. Am J Gastroenterol. Dec1999;94:3530–3540. https://doi.org/10.1111/j.1572-0241.1999.01642.x.CrossRefPubMed

Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol. Apr2004;99:750–759. https://doi.org/10.1111/j.1572-0241.2004.04114.x.CrossRefPubMed

Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part II: lower gastrointestinal diseases. Gastroenterology. Mar2009;136:741–754. https://doi.org/10.1053/j.gastro.2009.01.015.CrossRefPubMed

Faigel DO. A clinical approach to constipation. Clin Cornerstone. 2002;4:11–21. https://doi.org/10.1016/s1098-3597(02)90002-5.CrossRefPubMed

Nellesen D, Yee K, Chawla A, Lewis BE, Carson RT. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation. J Manag Care Pharm. Nov-Dec 2013;19:755–764. https://doi.org/10.18553/jmcp.2013.19.9.755.CrossRef

Vollebregt PF, Burgell RE, Hooper RL, Knowles CH, Scott SM. Clinical Impact of Rectal Hyposensitivity: A Cross-Sectional Study of 2,876 Patients With Refractory Functional Constipation. Am J Gastroenterol. Apr2021;116:758–768. https://doi.org/10.14309/ajg.0000000000001039.CrossRefPubMed

Burgell RE, Lelic D, Carrington EV, et al. Assessment of rectal afferent neuronal function and brain activity in patients with constipation and rectal hyposensitivity. Neurogastroenterol Motil. Mar 2013;25:260–7, e167–8. https://doi.org/10.1111/nmo.12047

Sandler RS, Jordan MC, Shelton BJ. Demographic and dietary determinants of constipation in the US population. Am J Public Health. Feb1990;80:185–189. https://doi.org/10.2105/ajph.80.2.185.CrossRefPubMedPubMedCentral

Robson KM, Kiely DK, Lembo T. Development of constipation in nursing home residents. Dis Colon Rectum. Jul2000;43:940–943. https://doi.org/10.1007/BF02237354.CrossRefPubMed

10.

Menke A, Rust KF, Fradkin J, Cheng YJ, Cowie CC. Associations between trends in race/ethnicity, aging, and body mass index with diabetes prevalence in the United States: a series of cross-sectional studies. Ann Intern Med. 2014;161:328–335. https://doi.org/10.7326/M14-0286.CrossRefPubMed

11.

Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995;122:481–486. https://doi.org/10.7326/0003-4819-122-7-199504010-00001.CrossRefPubMed

12.

Poirier P, Giles TD, Bray GA et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol. May2006;26:968–976. https://doi.org/10.1161/01.ATV.0000216787.85457.f3.CrossRefPubMed

13.

Nguyen NT, Magno CP, Lane KT, Hinojosa MW, Lane JS. Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J Am Coll Surg. Dec2008;207:928–934. https://doi.org/10.1016/j.jamcollsurg.2008.08.022.CrossRefPubMed

14.

Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. Apr2001;24:683–689. https://doi.org/10.2337/diacare.24.4.683.CrossRefPubMed

15.

Nowbar S, Burkart KM, Gonzales R et al. Obesity-associated hypoventilation in hospitalized patients: prevalence, effects, and outcome. Am J Med. 2004;116:1–7. https://doi.org/10.1016/j.amjmed.2003.08.022.CrossRefPubMed

16.

Macavei VM, Spurling KJ, Loft J, Makker HK. Diagnostic predictors of obesity-hypoventilation syndrome in patients suspected of having sleep disordered breathing. J Clin Sleep Med. 2013;9:879–884. https://doi.org/10.5664/jcsm.2986.CrossRefPubMedPubMedCentral

17.

Steele CB, Thomas CC, Henley SJ et al. Vital Signs: Trends in Incidence of Cancers Associated with Overweight and Obesity - United States, 2005–2014. MMWR Morb Mortal Wkly Rep. 2017;66:1052–1058. https://doi.org/10.15585/mmwr.mm6639e1.CrossRefPubMedPubMedCentral

18.

Kulkarni K, Karssiens T, Kumar V, Pandit H. Obesity and osteoarthritis. Maturitas. Jul 2016;89:22–8. https://doi.org/10.1016/j.maturitas.2016.04.006

19.

Aune D, Norat T, Vatten LJ. Body mass index, abdominal fatness and the risk of gallbladder disease. Eur J Epidemiol. Sep2015;30:1009–1019. https://doi.org/10.1007/s10654-015-0081-y.CrossRefPubMed

20.

Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. N Engl J Med. Dec 19 2019;381:2440–2450. https://doi.org/10.1056/NEJMsa1909301

21.

Garvey WT, Mechanick JI, Brett EM et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract. Jul2016;22:1–203. https://doi.org/10.4158/EP161365.GL.CrossRefPubMed

22.

Milic S, Lulic D, Stimac D. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol. 2014;20:9330–9337. https://doi.org/10.3748/wjg.v20.i28.9330.CrossRefPubMedPubMedCentral

23.

Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143:199–211. https://doi.org/10.7326/0003-4819-143-3-200508020-00006.CrossRefPubMed

24.

Bharucha AE, Wald A. Chronic Constipation. Mayo Clin Proc. Nov2019;94:2340–2357. https://doi.org/10.1016/j.mayocp.2019.01.031.CrossRefPubMed

25.

Chu DT, Minh Nguyet NT, Nga VT et al. An update on obesity: Mental consequences and psychological interventions. Diabetes Metab Syndr. Jan-Feb 2019;13:155–160. https://doi.org/10.1016/j.dsx.2018.07.015.CrossRef

26.

Mazor Y, Trieu RQ, Prott G et al. Volumetric Rectal Perception Testing: Is It Clinically Relevant? Results From a Large Patient Cohort. Am J Gastroenterol. 2021;116:2419–2429. https://doi.org/10.14309/ajg.0000000000001526.CrossRefPubMed

27.

Brochard C, Vénara A, Bodère A, Ropert A, Bouguen G, Siproudhis L. Pathophysiology of fecal incontinence in obese patients: A prospective case-matched study of 201 patients. Neurogastroenterol Motil. Aug 2017;29(8)https://doi.org/10.1111/nmo.13051

28.

Neto IJFC, Pinto RA, Jorge JMN et al. Are Obese Patients at an Increased Risk of Pelvic Floor Dysfunction Compared to Non-obese Patients? Obes Surg. Jul2017;27:1822–1827. https://doi.org/10.1007/s11695-017-2559-z.CrossRefPubMed

29.

Price RC, Asenjo JF, Christou NV, Backman SB, Schweinhardt P. The role of excess subcutaneous fat in pain and sensory sensitivity in obesity. Eur J Pain. Oct2013;17:1316–1326. https://doi.org/10.1002/j.1532-2149.2013.00315.x.CrossRefPubMed

30.

Akhondi N, Memar Montazerin S, Soltani S et al. General and abdominal obesity in relation to the prevalence of irritable bowel syndrome. Neurogastroenterol Motil. Apr2019;31:e13549. https://doi.org/10.1111/nmo.13549.CrossRefPubMed

31.

Tramullas M, Finger BC, Dinan TG, Cryan JF. Obesity Takes Its Toll on Visceral Pain: High-Fat Diet Induces Toll-Like Receptor 4-Dependent Visceral Hypersensitivity. PLoS One. 2016;11:e0155367. https://doi.org/10.1371/journal.pone.0155367.CrossRefPubMedPubMedCentral

32.

Teitelbaum JE, Sinha P, Micale M, Yeung S, Jaeger J. Obesity is related to multiple functional abdominal diseases. J Pediatr. Mar2009;154:444–446. https://doi.org/10.1016/j.jpeds.2008.09.053.CrossRefPubMed

33.

Tashani OA, Astita R, Sharp D, Johnson MI. Body mass index and distribution of body fat can influence sensory detection and pain sensitivity. Eur J Pain. Aug2017;21:1186–1196. https://doi.org/10.1002/ejp.1019.CrossRefPubMed

34.

Yanping W, Gao X, Cheng Y, et al. The interaction between obesity and visceral hypersensitivity. J Gastroenterol Hepatol. Dec 7 2022;https://doi.org/10.1111/jgh.16083

35.

Torensma B, Thomassen I, van Velzen M, In 't Veld BA. Pain Experience and Perception in the Obese Subject Systematic Review (Revised Version). Obes Surg. Mar 2016;26:631–9. https://doi.org/10.1007/s11695-015-2008-9

Titel: Obesity Is Associated with Altered Rectal Sensitivity in Chronic Constipation
verfasst von: Nayna A. Lodhia
Brent Hiramoto
Laura Horton
Alison H. Goldin
Christopher C. Thompson
Walter W. Chan
Publikationsdatum: 06.01.2024
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 3/2024
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-023-08246-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

CKD bei Diabetes: Neuheiten und Zukunftsaussichten

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Jeder Mensch mit Diabetes muss auf eine chronische Nierenerkrankung gescreent werden – diese neue Empfehlung spricht die KDIGO aus. Die Therapie erfolgt individuell und je nach Szenario mit verschiedenen Substanzklassen. Künftig kommt wahrscheinlich, neben RAS-Hemmung, SGLT2-Inhibition und nsMRA, eine vierte Therapiesäule hinzu.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

SGLT2-Inhibitoren und GLP-1-Rezeptoragonisten im Schlagabtausch

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Wer hat die Nase vorn – SGLT2-Inhibitoren oder GLP-1-Rezeptoragonisten? Diese Frage diskutierten zwei Experten in einer Session auf dem diesjährigen Diabetes-Kongress.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2024

A Comprehensive Global Population-Based Analysis on the Coexistence of Eosinophilic Esophagitis and Inflammatory Bowel Disease

To Perform or Not to Perform Sphincterotomy in Hilar Malignant Strictures?

Treating a Bypass with Bypass Surgery: Repair of a Duodeno-sigmoid Fistula Complicating Acute Diverticulitis

What’s UP with Ulcerative Proctitis?: It’s Not Always What You Think

Disparity Among African Americans in Transjugular Intrahepatic Portosystemic Shunt Procedure: A National Inpatient Sample Analysis from 2015 to 2020